Seaport Therapeutics
Agent39Agent Readiness: 39/100. Below median. Measured by StartupHub.ai. Median 41.Trust76Data Trust: 76/100. Above median. Measured by StartupHub.ai. Median 61.Developing novel therapeutics to restore gut lymphatic function.
About
Seaport Therapeutics is a biotechnology company focused on developing novel therapeutics that restore gut lymphatic function. Their lead candidate, GlyphCele™, is the first oral therapeutic designed for this purpose and has received significant funding from ARPA-H to advance its development.
Listed competitors
Enveda Biosciences is a biotechnology company using AI and metabolomics to discover new medicines from natural sources.
Alto Neuroscience is a clinical-stage biopharmaceutical company developing precision psychiatry medicines for mental health conditions.
Biopharmaceutical company developing and commercializing CNS disease treatments.
Also in this space
Moderna is a biotechnology company pioneering mRNA medicine, best known for its COVID-19 vaccine and a broad pipeline of mRNA-based therapeutics.
Shares Biotechnology, Pharmaceuticals
Biotechnology company developing and commercializing cell therapies for cancer treatment.
Shares Biotechnology, Pharmaceuticals
Biotechnology company focused on developing cancer immunotherapies.
Shares Biotechnology, Pharmaceuticals
Biotechnology company developing transformative gene-based medicines using CRISPR/Cas9 gene editing technology.
Shares Biotechnology, Pharmaceuticals
Clinical-stage biotechnology company advancing molecular glue degrader (MGD) medicines.
Shares Biotechnology, Pharmaceuticals
Clinical-stage biopharmaceutical company developing microbiome-derived immunotherapies for cancer and immune diseases.
Shares Biotechnology, Pharmaceuticals
Key facts
- Website
- seaporttx.com
- Headquarters
- Cambridge, Massachusetts, USA
- Founded
- 2021
- Employees
- 64
- Total funding
- $340M (Unknown)
- Business model
- B2B
Funding rounds
| Date | Round | Amount | Lead investors |
|---|---|---|---|
| 3 Mar 2026 | Undisclosed round | $15M | ARPA-H |
| 21 Oct 2024 | Series B | $225M | General Atlantic |
| 9 Apr 2024 | Series A | $100M | Arch Venture Partners |
Tech stack
Detected on seaporttx.com, last scanned 29 Oct 2026. Run your own scan
- Frontend
- jQuery, Bootstrap
- Analytics
- Google Analytics 4
- CMS / Builders
- WordPress
- CDN
- Cloudflare
- Email provider
- Microsoft 365
- Hiring platform
- Greenhouse
Seaport Therapeutics scores 34. Does yours?
That is its Ahrefs DR: the backlink strength of a domain, on the Ahrefs 0 to 100 scale. Paste your website and you get yours in about a minute.
Frequently asked
Is Seaport Therapeutics trustworthy and reputable?
StartupHub's Data Trust & Reputation score for Seaport Therapeutics is 76 out of 100, a generally safe rating, based on site security posture, privacy practices, malware and phishing checks, and public reputation signals.
How much funding has Seaport Therapeutics raised?
Seaport Therapeutics has raised a total of $340M in funding. The most recent round on record is Unknown.
How many employees does Seaport Therapeutics have?
Seaport Therapeutics has approximately 64 people on record.
Public record
SEC filings, insider activity, nonprofit links and pay benchmarks for Seaport Therapeutics
